Antinociceptive evaluation of cyriotoxin-1a and huwentoxin-IV, two spider toxins that block with high affinity the Nav1.7 subtype of voltage-gated sodium channels
2018
Gonçalves, Tânia C. | Benoit, Evelyne | Servent, Denis | Partiseti, Michel | Service d'Ingénierie Moléculaire pour la Santé | Médicaments et Technologies pour la Santé | Université Paris-Saclay-Institut des Sciences du Vivant Frédéric JOLIOT | Commissariat à l'énergie atomique et aux énergies alternatives -Commissariat à l'énergie atomique et aux énergies alternatives -Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement -Université Paris-Saclay-Institut des Sciences du Vivant Frédéric JOLIOT | Commissariat à l'énergie atomique et aux énergies alternatives -Commissariat à l'énergie atomique et aux énergies alternatives -Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement | Servce d'ingénierie moléculaire des protéines | Commissariat à l'énergie atomique et aux énergies alternatives -Université Paris-Saclay-Centre National de la Recherche Scientifique -Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement | Sanofi-Aventis R&D | SANOFI Recherche | Association Canaux Ioniques
International audience
Show more [+] Less [-]English. Over the last decades, animal venom toxins have been explored as an original source of new antinociceptive drugs. Our target of interest, NaV1.7, has been validated by human genetic evidence and is mainly expressed in dorsal root ganglia (DRG) neurons. High throughput screening of Sanofi's collection of venom toxins was performed on HEK cells overexpressing human Na V subtypes. The results highlight a new toxin, cyriotoxin-1a (CyrTx-1a), sharing the same inhibitory cysteine knot (ICK) motif with toxins originating from the same theraphosids spider family, such as huwentoxin-IV (HwTx-IV), a potential antalgic targeting Na V1.7. However, when tested in mouse isolated neuromuscular preparations at low concentrations (that did not affect the Na V1.4 muscle subtype), HwTx-IV inhibited completely the muscle contraction, thus incriminating the Na V1.6 neuronal subtype. CyrTx-1a and HwTx-IV revealed nanomolar range affinity for NaV1.7, 1.6, 1.1, 1.2 and 1.3 and micromolar range affinity for Na V1.5, 1.4 and 1.8. Moreover, in mouse DRG neurons, the peptides inhibited preferentially tetrodotoxin (TTX)-sensitive Na current flowing mainly through NaV1.7, compared with TTX-resistant Na current flowing through Na V1.8 and 1.9. Within a therapeutic window of concentrations sparing skeletal muscular system, the peptides exhibited a similar analgesic-like effect in mouse pain models (hot plate and von Frey essays). However, compared with HwTx-IV, CyrTx-1a had less marked in vivo sideeffects, as detected by analyzing in vivo the excitability properties of the mouse neuromuscular system, mediated by NaV1.4 and 1.6. In conclusion, the better in vivo pharmacological profile of CyrTx-1a paves the way for further engineering studies aimed to optimize its potential antinociceptive capability.
Show more [+] Less [-]Bibliographic information
This bibliographic record has been provided by National Institute for Agricultural Research